Clozapine is not a controlled substance. It does not appear on any of the five schedules of the Controlled Substances Act, and the Drug Enforcement Administration does not regulate it as a drug of abuse. However, clozapine has historically been one of the most tightly restricted prescription medications in the United States, which is why the question comes up so often.
Why Clozapine Feels Like a Controlled Substance
The confusion is understandable. Until mid-2025, clozapine was subject to a mandatory FDA program called a Risk Evaluation and Mitigation Strategy (REMS) that imposed restrictions far more burdensome than those on most Schedule II controlled substances like oxycodone or amphetamines. Prescribers had to register in a national database. Pharmacies had to be certified. Patients had to enroll individually. And before a pharmacy could hand over a single dose, a blood test result had to be submitted to a central system confirming it was safe to dispense. No blood result, no medication.
These restrictions had nothing to do with addiction or diversion, the reasons drugs land on the controlled substances schedules. They existed because clozapine carries a rare but serious risk of severely depleting white blood cells, a condition called severe neutropenia. Without enough white blood cells, ordinary infections can become life-threatening. In a large study across Australia and New Zealand involving over 26,000 patients, about 1.2% developed serious neutropenia requiring them to stop the drug.
What Changed in 2025
In February 2025, the FDA announced it no longer expected prescribers, pharmacies, or patients to participate in the REMS program. The formal removal took effect on June 13, 2025. Prescribers no longer need to enroll in a registry or submit blood test results to a central database before pharmacies can dispense clozapine. Pharmacies no longer need certification or special authorization to order and dispense it.
The FDA determined that clozapine’s labeling, including a new Medication Guide, is sufficient to communicate the risks without the infrastructure of a mandatory registry. The agency still recommends that prescribers monitor patients’ white blood cell counts on a regular schedule: weekly for the first six months, every two weeks for months six through twelve, and monthly after the first year. This monitoring is now a clinical recommendation rather than a legal prerequisite for getting the prescription filled.
How Clozapine Is Classified
Clozapine is a prescription-only medication classified as an atypical antipsychotic. It is primarily used for treatment-resistant schizophrenia, meaning it is typically reserved for people who haven’t responded adequately to other antipsychotic medications. It does not produce euphoria, physical dependence, or the kind of reinforcing effects that lead to misuse, which is why it has never been placed on a DEA schedule.
Its prescribing information carries five separate black box warnings, the FDA’s most serious safety alert. These cover severe neutropenia, dangerous drops in blood pressure upon standing, seizures (which are dose-related), heart inflammation including potentially fatal myocarditis and cardiomyopathy, and increased mortality risk when used in elderly patients with dementia-related psychosis. No other antipsychotic carries this many boxed warnings, which further explains why access has been so heavily gatekept despite the drug not being “controlled” in the legal sense.
What This Means for Patients
If you take clozapine, the day-to-day experience of filling your prescription has become significantly simpler since the REMS removal. You no longer need to have a blood draw reported to a central system before your pharmacy can release your medication. Gaps in blood work no longer trigger automatic dispensing blocks that could leave you without your medication for days.
That said, regular blood monitoring remains an important safety measure. The risk of neutropenia is highest in the first several months of treatment but can occur at any point. Routine blood counts allow your prescriber to catch a downward trend in white blood cells early, before it becomes dangerous. Most prescribers will continue to order these labs on the same schedule the REMS previously required.
If you’re picking up clozapine at a pharmacy for the first time and a pharmacist asks about blood work or registration, it may be worth noting that the REMS program was formally eliminated in June 2025. Some pharmacies may take time to update their internal protocols. But legally, no registry enrollment or blood test submission is required for dispensing.